 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...7576777879808182838485...100101» |
- ||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Phase classification, Enrollment change, Trial completion date, Combination therapy, Metastases: A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Mar 26, 2019
P1/2, N=146, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Phase classification: P1b/2 --> P1/2 | N=106 --> 146 | Trial completion date: Dec 2020 --> Jun 2021
- | letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome (clinicaltrials.gov) - Mar 25, 2019
P3, N=150, Recruiting, Sponsor: Assiut University
Phase classification: P1b/2 --> P1/2 | N=106 --> 146 | Trial completion date: Dec 2020 --> Jun 2021 Trial completion date: Feb 2019 --> Feb 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- || Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date, HEOR, Patient reported outcomes, Metastases: PRECYCLE: Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (clinicaltrials.gov) - Mar 25, 2019
P4, N=960, Recruiting, Sponsor: Palleos Healthcare GmbH
Trial completion date: Feb 2019 --> Feb 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Jun 2021 --> Dec 2024
- | letrozole / generics
Preclinical, Journal: The Flavanone, Naringenin, Modifies Antioxidant and Steroidogenic Enzyme Activity in a Rat Model of Letrozole-Induced Polycystic Ovary Syndrome. (Pubmed Central) - Mar 25, 2019
Naringenin treatment resulted in a significant reduction in serum glucose levels (p<0.05), normalized estradiol and testosterone levels steroidogenic enzyme activity, and maintained the normal anatomy of the ovaries. CONCLUSIONS Naringenin treatment, in a rat model of PCOS, demonstrated antioxidant and steroidogenic enzyme activity.
- | Afinitor (everolimus) / Novartis
Clinical, P2 data, Journal: Everolimus Plus Letrozole for Treatment of Patients With HR(+), HER2(-) Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial. (Pubmed Central) - Mar 23, 2019
CONCLUSIONS Naringenin treatment, in a rat model of PCOS, demonstrated antioxidant and steroidogenic enzyme activity. Everolimus plus letrozole demonstrated clinical benefit and could be a valid treatment option for postmenopausal women recurring/progressing on prior endocrine therapy.
- | Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
Enrollment closed, Enrollment change, Combination therapy, Metastases: Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) - Mar 20, 2019
P1/2, N=25, Active, not recruiting, Sponsor: Academic Thoracic Oncology Medical Investigators Consortium
Everolimus plus letrozole demonstrated clinical benefit and could be a valid treatment option for postmenopausal women recurring/progressing on prior endocrine therapy. Recruiting --> Active, not recruiting | N=40 --> 25
- | Herceptin (trastuzumab) / Roche
New P2 trial: ARETTA: Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer (clinicaltrials.gov) - Mar 19, 2019
P2, N=60, Not yet recruiting, Sponsor: University of Chicago
- | cisplatin / Generic mfg., paclitaxel / Generic mfg.
Enrollment closed, Metastases: SHPD002: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Mar 14, 2019
P2/3, N=250, Active, not recruiting, Sponsor: RenJi Hospital
Recruiting --> Active, not recruiting | N=40 --> 25 Recruiting --> Active, not recruiting
- || Imfinzi (durvalumab) / AstraZeneca
New P2 trial, Combination therapy: Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer (clinicaltrials.gov) - Mar 13, 2019
P2, N=46, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: PHERGain: Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (clinicaltrials.gov) - Mar 11, 2019
P2, N=400, Recruiting, Sponsor: MedSIR
Recruiting --> Active, not recruiting Trial completion date: Dec 2021 --> Oct 2022 | Trial primary completion date: Jul 2021 --> Oct 2021
- | Kisqali (ribociclib) / Novartis
Clinical, P3 data, Journal: First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. (Pubmed Central) - Mar 8, 2019
RIB plus LET versus PBO plus LET is associated with earlier and more durable tumor response, greater degree of tumor shrinkage and pain reduction, and PFS benefit irrespective of TFI. These data further support RIB plus LET as a first-line treatment option for postmenopausal women with HR+ , HER2- ABC.
- | everolimus / Generic mfg., sapanisertib (TAK-228) / Takeda
Journal: Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer. (Pubmed Central) - Mar 8, 2019
These data further support RIB plus LET as a first-line treatment option for postmenopausal women with HR+ , HER2- ABC. Among the many signaling transduction pathways, which are altered post everolimus resistance, targeting dual mTORC1/2 is a possible option for patients who have recurrent disease from previous everolimus treatment.
- | Kisqali (ribociclib) / Novartis
Clinical, Journal, HEOR: Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. (Pubmed Central) - Mar 8, 2019
P3
HRQoL was consistently maintained from baseline in postmenopausal women with HR+, HER2- advanced breast cancer receiving ribociclib plus letrozole and was similar to that observed in the placebo plus letrozole arm. Together with the improved clinical efficacy and manageable safety profile, these PRO results provide additional support for the benefit of ribociclib plus letrozole in this patient population.
- | Avastin (bevacizumab) / Roche
Clinical, Journal: Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. (Pubmed Central) - Mar 8, 2019
Age (≥ 65 years), decreased vision, and impairments in physical function correlated with increased incidence of toxicity in patients receiving first-line letrozole plus bevacizumab. When evaluating therapy likely to increase toxicity, functional assessment measures can identify patients at increased risk for side effects who may benefit from closer monitoring.
- | Soltamox (tamoxifen citrate) / Jazz
Trial completion date, Trial primary completion date: PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov) - Mar 8, 2019
P2, N=39, Recruiting, Sponsor: Medical College of Wisconsin
When evaluating therapy likely to increase toxicity, functional assessment measures can identify patients at increased risk for side effects who may benefit from closer monitoring. Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Dec 2019 --> Jul 2020
- || Ibrance (palbociclib) / Pfizer
Trial initiation date, Trial primary completion date, Surgery: DxCARTES: Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 - (clinicaltrials.gov) - Mar 7, 2019
P2, N=66, Not yet recruiting, Sponsor: MedSIR
Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Dec 2019 --> Jul 2020 Initiation date: Jan 2019 --> Apr 2019 | Trial primary completion date: Jan 2019 --> May 2019
- ||| Kisqali (ribociclib) / Novartis
Enrollment open: GOG-3026: Ribociclib and Letrozole Treatment in Ovarian Cancer (clinicaltrials.gov) - Mar 6, 2019
P2, N=51, Recruiting, Sponsor: Gynecologic Oncology Group
Initiation date: Jan 2019 --> Apr 2019 | Trial primary completion date: Jan 2019 --> May 2019 Not yet recruiting --> Recruiting
- | samotolisib (LY3023414) / Eli Lilly
Trial completion date, Metastases: A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) - Mar 5, 2019
P1, N=130, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Trial completion date: Mar 2021 --> Mar 2020
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Metastases: To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer (clinicaltrials.gov) - Mar 5, 2019
P1, N=79, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Mar 2021 --> Mar 2020 Trial completion date: Dec 2018 --> Dec 2019
- ||| Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Mar 5, 2019
P3, N=3254, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2018 --> Dec 2019 Trial completion date: Nov 2019 --> May 2021
- ||||| Ibrance (palbociclib) / Pfizer
Biomarker, Enrollment closed, Combination therapy, Circulating tumor DNA, Metastases: PADA-1: PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection (clinicaltrials.gov) - Mar 4, 2019
P3, N=800, Active, not recruiting, Sponsor: UNICANCER
Trial completion date: Nov 2019 --> May 2021 Recruiting --> Active, not recruiting
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer (clinicaltrials.gov) - Feb 28, 2019
P2, N=75, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2019 --> Jan 2020
- ||| Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Feb 26, 2019
P3, N=672, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2019 --> Jan 2020 Trial completion date: Sep 2019 --> Dec 2020
- || gedatolisib (PF-05212384) / Celcuity
Trial completion date, Trial primary completion date, Combination therapy, Metastases: B2151009: A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer (clinicaltrials.gov) - Feb 25, 2019
P1b, N=148, Recruiting, Sponsor: Pfizer
Trial completion date: Sep 2019 --> Dec 2020 Trial completion date: Oct 2019 --> Jun 2020 | Trial primary completion date: Oct 2019 --> Jun 2020
- ||| Herceptin (trastuzumab) / Roche
Enrollment change, Trial completion date: HELEX: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy (clinicaltrials.gov) - Feb 19, 2019
P2, N=128, Active, not recruiting, Sponsor: Baylor Breast Care Center
Trial completion date: Oct 2019 --> Jun 2020 | Trial primary completion date: Oct 2019 --> Jun 2020 N=96 --> 128 | Trial completion date: Jan 2018 --> Jan 2020
- || Ibrance (palbociclib) / Pfizer
Enrollment open, Trial completion date, Trial primary completion date: ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov) - Feb 19, 2019
P2, N=42, Recruiting, Sponsor: Emory University
N=96 --> 128 | Trial completion date: Jan 2018 --> Jan 2020 Not yet recruiting --> Recruiting | Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
- || Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Enrollment closed, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Feb 15, 2019
P1, N=256, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020 Recruiting --> Active, not recruiting
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment open, Trial initiation date, Combination therapy, Metastases: PLEASURABLE: Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer (clinicaltrials.gov) - Feb 15, 2019
P1/2, N=32, Recruiting, Sponsor: Fudan University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Dec 2018 --> Mar 2019
- ||||| Kisqali (ribociclib) / Novartis
New P2 trial, Metastases: RIGHT Choice: Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Feb 15, 2019
P2, N=222, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Metastases: POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) - Feb 8, 2019
P2, N=59, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Not yet recruiting --> Recruiting | Initiation date: Dec 2018 --> Mar 2019 Trial completion date: Mar 2019 --> Dec 2021 | Trial primary completion date: Jan 2019 --> Aug 2021
- | Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Feb 8, 2019
P2, N=48, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Mar 2019 --> Dec 2021 | Trial primary completion date: Jan 2019 --> Aug 2021 Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Feb 2021 | Trial primary completion date: Jul 2019 --> Mar 2019
- | NN1213 / Novo Nordisk
Trial completion, Trial initiation date: RIOT-A: Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment (clinicaltrials.gov) - Feb 6, 2019
P2/3, N=130, Completed, Sponsor: Sven O. Skouby
Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Feb 2021 | Trial primary completion date: Jul 2019 --> Mar 2019 Recruiting --> Completed | Initiation date: Aug 2016 --> Feb 2017
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Enrollment open, Trial initiation date, Stroma, Metastases: BFR-ESS: Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS) (clinicaltrials.gov) - Feb 6, 2019
P2, N=40, Recruiting, Sponsor: Centre Leon Berard
Recruiting --> Completed | Initiation date: Aug 2016 --> Feb 2017 Not yet recruiting --> Recruiting | Initiation date: Oct 2018 --> Jan 2019
- || NN1213 / Novo Nordisk
Enrollment change, Trial completion date, Trial primary completion date, Real-world evidence, Real-world, Metastases: Treat ER+ight: Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy (clinicaltrials.gov) - Feb 5, 2019
P=N/A, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Oct 2018 --> Jan 2019 N=320 --> 500 | Trial completion date: Dec 2019 --> Jan 2023 | Trial primary completion date: Dec 2019 --> Jan 2023
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Combination therapy, Metastases: Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Feb 5, 2019
P4, N=252, Active, not recruiting, Sponsor: Pfizer
N=320 --> 500 | Trial completion date: Dec 2019 --> Jan 2023 | Trial primary completion date: Dec 2019 --> Jan 2023 Recruiting --> Active, not recruiting
- |||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Combination therapy, Metastases: Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate (clinicaltrials.gov) - Feb 5, 2019
P3, N=131, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Kisqali (ribociclib) / Novartis
Enrollment closed, Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Feb 5, 2019
P3, N=3256, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Feb 2014
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date: RIOT-B: Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles (clinicaltrials.gov) - Feb 5, 2019
P2/3, N=33, Completed, Sponsor: Sven O. Skouby
Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Feb 2014 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018
- ||| Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Enrollment open, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Feb 4, 2019
P1, N=270, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 Active, not recruiting --> Recruiting
- |||||| Kisqali (ribociclib) / Novartis
Enrollment open, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Feb 1, 2019
P3, N=3775, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Active, not recruiting --> Recruiting
- || Kisqali (ribociclib) / Novartis
Trial completion date, Trial initiation date, Trial primary completion date, Tumor mutational burden: LEEomic: CompLEEment-1 Canadian Correlative Sub-Study (clinicaltrials.gov) - Feb 1, 2019
P2, N=150, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Trial completion date: Dec 2018 --> Apr 2019 | Initiation date: Oct 2018 --> Apr 2019 | Trial primary completion date: Dec 2018 --> Apr 2019
- || Piqray (alpelisib) / Novartis
Trial completion date, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Jan 30, 2019
P2, N=336, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2018 --> Apr 2019 | Initiation date: Oct 2018 --> Apr 2019 | Trial primary completion date: Dec 2018 --> Apr 2019 Trial completion date: Apr 2020 --> Nov 2020
- ||||| Kisqali (ribociclib) / Novartis
New P2 trial, Combination therapy, Metastases: AMALEE: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Jan 29, 2019
P2, N=350, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | letrozole / Generic mfg.
Trial primary completion date: SOLE: Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer (clinicaltrials.gov) - Jan 29, 2019
P3, N=4884, Active, not recruiting, Sponsor: International Breast Cancer Study Group
Trial completion date: Apr 2020 --> Nov 2020 Trial primary completion date: Apr 2019 --> Apr 2018
- |||| Ibrance (palbociclib) / Pfizer
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Jan 29, 2019
P4, N=300, Recruiting, Sponsor: Pfizer
Trial primary completion date: Apr 2019 --> Apr 2018 Active, not recruiting --> Recruiting | Trial completion date: Dec 2019 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2020
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Combination therapy, Metastases: Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Jan 28, 2019
P4, N=242, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Recruiting | Trial completion date: Dec 2019 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2020 Recruiting --> Active, not recruiting
- |||| Ibrance (palbociclib) / Pfizer
New P2 trial, Surgery: DxCARTES: Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 - (clinicaltrials.gov) - Jan 28, 2019
P2, N=66, Not yet recruiting, Sponsor: MedSIR
- | Verzenio (abemaciclib) / Eli Lilly
Clinical, Journal: MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. (Pubmed Central) - Jan 27, 2019
The most frequent grade ≥ 3 adverse events in the abemaciclib versus placebo arms were neutropenia (23.9% versus 1.2%), diarrhea (9.5% versus 1.2%), and leukopenia (8.6% versus 0.6%). Abemaciclib plus a nonsteroidal AI was an effective initial treatment with an acceptable safety profile for HR+, HER2- ABC.
- ||||| Kisqali (ribociclib) / Novartis
Enrollment closed, Enrollment change: A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib (clinicaltrials.gov) - Jan 25, 2019
P3, N=8, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Abemaciclib plus a nonsteroidal AI was an effective initial treatment with an acceptable safety profile for HR+, HER2- ABC. Recruiting --> Active, not recruiting | N=140 --> 8
- ||| Piqray (alpelisib) / Novartis
Enrollment change, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Jan 23, 2019
P2, N=336, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=140 --> 8 N=160 --> 336